troglitazone has been researched along with Diabetic Retinopathy in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inukai, T | 1 |
| Takanashi, K | 1 |
| Tayama, K | 1 |
| Aso, Y | 1 |
| Takemura, Y | 1 |
1 trial available for troglitazone and Diabetic Retinopathy
| Article | Year |
|---|---|
High glucose concentrations abolish the superoxide dismutase response of leukocytes to ascorbic acid or troglitazone in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Antioxidants; Ascorbic Acid; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephro | 2002 |